William Blair analyst Ryan Daniels has reiterated their bullish stance on OPRX stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ryan Daniels has given his Buy rating due to a combination of factors tied to OptimizeRx’s execution and financial performance. The company delivered a notably strong fourth quarter, with revenue and adjusted EBITDA surpassing Wall Street expectations, driven in part by better‑than‑anticipated gross margins and prudent balance sheet actions, including debt repayment and a share repurchase plan.
Daniels also views current end‑market headwinds as largely temporary, citing industry‑wide MFN‑related spending caution and disruption from a major agency merger as short‑term issues rather than structural problems. While management trimmed its 2026 revenue outlook to reflect this volatility, it simultaneously raised EBITDA guidance, reinforcing confidence in profitability and supporting the case for continued upside in the stock over the coming year.
According to TipRanks, Daniels is a 2-star analyst with an average return of 0.4% and a 40.59% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Healthcare Services, Evolent Health, and Astrana Health.
In another report released today, Lake Street also maintained a Buy rating on the stock with a $24.00 price target.